Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07494305 N-methyl amisulpride Bipolar I disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07494305 clinical trial report covering N-methyl amisulpride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600121242 Letrozole HER2 Positive Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
ChiCTR2600121242 clinical trial report covering Letrozole, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07496190 Becotatug vedotin Advanced Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07496190 clinical trial report covering Becotatug vedotin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07493980 JSKN016 Resectable Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07493980 clinical trial report covering JSKN016, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07498517 Xisomab 3G3(Oregon Health & Science University) Catheter related thrombosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07498517 clinical trial report covering Xisomab 3G3(Oregon Health & Science University), Phase 2, endpoints, sponsor, geography, readout timing and deve
Latest Hotspot
8 min read
NCT07498478 Fulvestrant Human epidermal growth factor 2 negative carcinoma of breast Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07498478 clinical trial report covering Fulvestrant, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07498647 BR2251 Hyperuricemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07498647 clinical trial report covering BR2251, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07497074 Bevacizumab Advanced Cervical Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07497074 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07495579 Regorafenib Advanced Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07495579 clinical trial report covering Regorafenib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07497282 Venlafaxine Hydrochloride Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07497282 clinical trial report covering Venlafaxine Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07497880 Safiglipron Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07497880 clinical trial report covering Safiglipron, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07497919 Becotatug vedotin Squamous Cell Carcinoma of the Penis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07497919 clinical trial report covering Becotatug vedotin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.